SMSPHARMA SMS Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
SMS Pharmaceuticals delivered a strong Q2 FY26, with PAT growing 80% YoY to INR25.3 crores and revenue up 23% to INR242.4 crores, driven by backward integration and product mix optimization. EBITDA margin expanded to 20%. The company is progressing on its INR280 crores capex program and aims for 20% growth and 20% EBITDA margin for FY26, despite some challenges in the Anti-diabetic segment and higher receivables.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 22.8%, net profit up 78.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 197 | 173 | 248 | 196 | 242 +23% |
| EBITDA | 31 | 33 | 41 | 39 | 48 +55% |
| Net profit | 14 | 18 | 20 | 20 | 25 +79% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
